Due to a system-wide technology update, we are experiencing extremely high call volume. We appreciate your patience with our operators during this time. Thank you for choosing Fox Chase Cancer Center.
Robert Uzzo Receives SUO Medal for Contributions to Urologic Oncology
PHILADELPHIA (May 16, 2018) – Robert G. Uzzo, MD, FACS, professor and chair of the Department of Surgical Oncology at Fox Chase Cancer Center, received the 2018 SUO Medal from the Society of Urologic Oncology (SUO) for his significant contributions to the field of urologic oncology. This prestigious award is presented to one member of SUO annually, and is among the organization’s highest honors.
As both a surgeon and researcher, Uzzo is an internationally renowned leader in the field of urologic oncology. His interests include organ preserving surgeries, robotic and minimally invasive surgeries, complex urological reconstructions, adjuvant therapies for his risk urologic tumors and, non-surgical management of low risk tumors. He is a national principal investigator on multiple adjuvant kidney cancer clinical trials evaluating both targeted anti-angiogenic and immunotherapies. He is currently the president of the SUO Clinical Trials Consortium and the author of more than 400 chapters, articles, books, and abstracts on urologic tumors, and has presented hundreds of regional, national, and international lectures.
A fellow of the American College of Surgeons and the prestigious American Association of Genitourinary Surgeons, Uzzo has consistently ranked among Castle Connolly’s and Philadelphia magazine's "Top Docs" in urology. He joined Fox Chase in 2000.
Since 1984, the SUO has been dedicated to research and education in urologic oncology, with the aim of caring for patients with malignant genitourinary diseases.
Uzzo will accept the SUO Medal at the upcoming combined spring meeting of the SUO and the American Urology Association. Among many honors, he is the recipient of the 2017 SUO President’s Distinguished Service Award and the 2014 AUA Residents Committee Teaching Award.
Fox Chase Cancer Center (Fox Chase), which includes the Institute for Cancer Research and the American Oncologic Hospital and is a part of Temple Health, is one of the leading comprehensive cancer centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase is also one of just 10 members of the Alliance of Dedicated Cancer Centers. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence five consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. It is the policy of Fox Chase Cancer Center that there shall be no exclusion from, or participation in, and no one denied the benefits of, the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.
For more information, call 888-369-2427